Disclaimers

DISCLAIMER: This site's contents are for informational purposes only. The Content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this Site!

If you think you may have a medical emergency, call your doctor or 911 immediately. The Site may contain health- or medical-related materials that are sexually explicit. If you find these materials offensive, please do not come to this Site. This site cannot guarantee the complete accuracy of these information-please check with your health providers. Reliance on any information provided by this Site is solely at your own risk.

Saturday, June 22, 2013

Chemotherapy-induced peripheral neuropathy (CIPN)



Chemotherapy-induced peripheral neuropathy (CIPN) is common especially in patients taking paclitaxel (Taxol) or cisplatin (Platinol).  CIPN may begin weeks to months after the initiation of treatment and often presents with a sensory neuropathy, including numbness and pain. The most common affected part of the body is hand and feet.  Paclitaxel may also cause diffuse aching discomfort in the legs, hips, and lower back, which develop within 1 to 3 days of paclitaxel administration and largely resolve within 7 days.  Although symptoms may resolve after completion of treatment, they are often only partially reversible, and can remain for years.

Recent study assessed efficacy of oral medications on chronic peripheral neuropathic pain by reviewing various published studies.  Seventeen studies comprised of 5,975 subjects, totaling 38 active trial arms evaluating 7 drugs, and 17 drug-dosing combinations met inclusion criteria. Mean pain reduction over placebo ranked highest for duloxetine 120 mg (1.17 95% CI 0.77, 1.58) and pregabalin 600 mg (1.11 95% CI 0.77, 1.45). The indirect treatment comparison showed largest effect size for duloxetine at 120 and 60 mg followed by pregabalin 600 mg. The study conclusion was pregabalin (lyrica) and duloxetine (cymbalta) had the largest beneficial effects for chronic peripheral neuropathic pain.

Just be aware that duloxetine has an FDA black box warning of suicidality.   Therefore, you should ask your doctor if you have depression or other mental disorder.  Pregabalin has no black box warning - at least at this time.

Reference:   
Ney JP, Devine EB, Watanabe JH, Sullivan SD. Comparative efficacy of oral pharmaceuticals for the treatment of chronic peripheral neuropathic pain: meta-analysis and indirect treatment comparisons. Pain Med. 2013 May;14(5):706-19

Severe fatigue during and after chemotherapy


Some of my patients, who are getting or after chemo treatment completion, complain of feeling severe exhaustion.  One patient reported of feeling good in the morning.  But she would get severe fatigue by the time she takes the morning shower.   NCCN defined this Cancer-Related-Fatigues (CRF) as a distressing, persistent, subjective sense of physical, emotional, and/or cognitive tiredness or exhaustion related to cancer or cancer treatment that is not proportional to recent activity and that interferes with usual functioning.

CRF seems to be common.  60% to 90% of cancer patients report fatigue with the highest rate of CRF occurring in patients undergoing chemotherapy. Although symptoms may improve after treatment, they can persist for months to years after the completion of therapy.  We don’t know the cause of CRF but recent research supports a role for dysregulation in inflammation and hypothalamic-pituitary-adrenal function.

The recommended CRF treatment is to treat possible comorbid medical conditions, including anemia, pain, depression, insomnia and hypothyroidism. However, the relationship between these symptoms is complex, and it is not clear whether treating comorbid symptoms will actually improve fatigue. For example, trials of nonpharmacologic interventions for insomnia that demonstrated improvement in sleep failed to show benefit for fatigue. Nonetheless, it is still important that other primary symptoms are addressed, such as depression.
No medications have been successful in treating CRF.  Psychostimulants, such as methylphenidate, dexamphetamine and modafinil, have not been clearly shown to improve CRF in clinical trials

Antidepressants have also been investigated for the treatment of CRF but showed no clear value in treating CRF. A randomized trial, studying paroxetine versus placebo in patients with cancer undergoing chemotherapy, found no influence on levels of CRF. Open label, pilot trials of bupropion in CRF appear promising, but need further validation. A large, randomized, controlled clinical trial compared donepezil (acetylcholinesterase inhibitor used to treat dementia ) with placebo, reporting no difference in levels of CRF between groups.

Studies on spplements such asL-carnitine, and coenzyme Q10 have been completed and showed no value.  Data from the ginseng trial is under analysis. Guarana is a plant from the Amazon basin used in the United States in energy drinks and weight loss products showed some promises based on a randomized, controlled trial by Brazilian investigators.

Interestingly, exercise may save the day.  Meta-analyses evaluating the effect of a variety of exercise programs on CRF found that physical exercise helped reduce CRF. Effect sizes ranged from 0.18 to 0.37, with the larger effect size in patients who completed treatment.    Common sense strategies such as education about fatigue, teaching self-care or coping techniques, and energy conservation or activity management seem to be effective.

Reference:


 

Sunday, June 9, 2013

Can you treat precancer disease of the uterus without surgery?

Uterine cancer is the most common gynecologic cancer in the United States.  There are over 40,000 American women develop this cancer yearly.   The most common types is the endometrial adenocarcinoma.  If you recall from my previous blog, this is mostly due to excess estrogen from obesity.  In a paper by Dr. Trimble, he quoted case control study which suggests a 200-400% increase risk of endometrial uterine cancer with BMI > 25.  BMI >25 means I weigh 160 lb with height of 5feet 6 inches.  I think you know many people are heavier than this BMI and are at risk of uterine cancer.

Before the uterus turns into cancer due to excess estrogen stimulation, the uterine lining thickens (we call it hyperplasia - excess growth).   This is a precancerous stage and usually accompanied by abnormal uterine bleeding.  In postmenopausal women with bleeding, your doctor usually recommend uterine endometrial biopsy.  Once confirmed, the most effective way is hysterectomy.

However, there are patients who are poor candidate for surgery because of poor health (poorly controlled diabetes, COPD, heart disease, etc).   Dr. Trimble reviewed the literatures and recommended the usage of progestin by mouth or intrauterine (using IUD).   Progestin is basically another hormone that is against the estrogen.   In my patients, I strongly recommend weight loss since many of the excess estrogen is produced by fat.

Reference:
Trimble CL, et al.  Management of endometrial precancers.  Obstet Gynecol. 2012; 120: 1160-75

Saturday, June 1, 2013

Is cancer contagious?

If my wife has cancer, can I get the same cancer from her?   In general, the answer is no.    In general, cancer is not contagious like infection.   You don't get colon or breast or ovarian cancer just because you are living with a patient with these cancers.  

However, cervical and liver cancer may be infectious indirect way.  Most cervical cancer is transmitted by Human Papilloma viruses (HPV).  HPV are transmitted, usually, by sexual intercourse.    Certain types of liver cancer can arise from liver cirrhosis.  This liver disease may be caused by another virus called Hepatitis C.  Hepatitis C is usually transmitted by exchanging body fluid (sex, blood transfusion, contaminated needles, etc).